UniProt P29597 · PDB · AlphaFold · Substrate: AXLtide · Clone: aa 833-1187
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ruxolitinib | 99.0% | 1.0% | 98.25 | 0.592 |
| 2 | Pacritinib | 98.8% | 1.2% | 88.64 | 0.452 |
| 3 | Entrectinib | 97.9% | 2.1% | 93.69 | 0.671 |
| 4 | Baricitinib | 97.3% | 2.7% | 97.99 | 0.616 |
| 5 | Upadacitinib | 97.1% | 2.9% | 97.98 | 0.663 |
| 6 | Pralsetinib | 96.8% | 3.2% | 93.43 | 0.643 |
| 7 | Repotrectinib | 96.3% | 3.7% | 84.21 | 0.608 |
| 8 | Defactinib | 95.0% | 5.0% | 92.68 | 0.450 |
| 9 | Fedratinib | 93.6% | 6.4% | 96.21 | 0.576 |
| 10 | Midostaurin | 93.4% | 6.6% | 78.64 | 0.500 |
| 11 | Abrocitinib | 89.9% | 10.1% | 99.50 | 0.581 |
| 12 | Ponatinib | 85.7% | 14.3% | 78.23 | 0.534 |
| 13 | Gilteritinib | 85.6% | 14.4% | 88.97 | 0.506 |
| 14 | Tofacitinib | 81.0% | 19.0% | 99.25 | 0.684 |
| 15 | Nintedanib | 68.7% | 31.3% | 90.23 | 0.608 |
| 16 | Vemurafenib | 65.3% | 34.7% | 96.49 | 0.598 |
| 17 | Crizotinib | 63.6% | 36.4% | 91.39 | 0.581 |
| 18 | Sunitinib | 63.3% | 36.7% | 91.73 | 0.524 |
| 19 | Umbralisib | 62.2% | 37.8% | 98.74 | 0.670 |
| 20 | Ripretinib | 58.9% | 41.1% | 92.95 | 0.674 |
Paralog block
TYK1_LTK, TYK2
EMT expression
- Mesenchymal log2(TPM+1): 5.74
- Epithelial log2(TPM+1): 5.62
- Fold change: 0.12
- Status: No significant change
Selectivity landscape vs inhibition on TYK2
Each point is one of the 92 approved drugs; color = inhibition % on TYK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…